RxDoctor Payments Data

Emory Klindworth, APRN

Family · Fayetteville, ARNPI 1700403946

Payments from drug & device makers

$1,851in general payments, 2019–2025

Across 59 payments — averaging $31.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$708
  • Johnson & Johnson$383
  • Novo Nordisk$188
  • Genentech USA, Inc.$143
  • Redhill Biopharma Inc.$113
  • Alkermes, Inc.$66
  • plus $250 from 9 others

What the payments were for

  • Food & beverage$1,851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,851 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$25,286
Medicare patients
173
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$19,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,291
JardianceEmpagliflozin11$11,587
OzempicSemaglutide11$8,609
Albuterol Sulfate HfaAlbuterol Sulfate25$517
Duloxetine Hcl31$508
Gabapentin44$406
SynthroidLevothyroxine Sodium12$378
Doxycycline Hyclate47$359
Methylprednisolone37$287
Prochlorperazine Maleate12$277
Atorvastatin Calcium29$222
Montelukast Sodium34$209
Levothyroxine Sodium27$207
Metoprolol Succinate12$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$64$19,29220 claims
GSKTrelegy Ellipta$21$13,29122 claims
Novo NordiskOzempic$188$8,60911 claims
AbbVieSynthroid$708$37812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.

Other family in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →